Redeye provides a research update following the Q1 report published by Alzinova earlier today. The financials in the report contained no major surprises, being in line with our expectations. Importantly, Alzinova’s scientific article based on clinical results from the Phase Ib study with ALZ-101 has now been accepted for publication. Moreover, the company has also opened up a new route for potential optionality value with the recently initiated collaboration with Amsterdam UMC to develop a blood-based Alzheimer’s diagnostic test. We reiterate our recently updated fair value range (SEK0.4 – SEK5) with a base case valuation of SEK2.
LÄS MER
